Quantum Healthcare Announces Massive Share Issuance, Debt-to-Equity Conversion, and Directors’ Fee Capitalisation

SGX Approval Received: Significant Corporate Actions Signal Strategic Shift for Investors

Quantum Healthcare Limited has made a major announcement that could have significant implications for shareholders and the company’s share price. The company’s board confirmed on 6 October 2025 that it has received the official Listing and Quotation Notice (LQN) from the Singapore Exchange Securities Trading Limited (SGX-ST) for a series of important corporate actions:

• Proposed Placement: Issuance of 2,727,272,800 new ordinary shares in the capital of the company to new investors.
• Debt Conversion: Conversion of outstanding debt into 1,595,912,182 new ordinary shares, specifically relating to a debt owed to PW Dental.
• Directors’ Fees Capitalisation: Settlement of S\$275,239.20 in unpaid directors’ fees by issuing new shares to certain present and former directors, namely Mr Victor Ng, Mr Ramasamy Jayapal, and Mr Melvin Lim Chun Siong.

Key Details Investors Must Note

• SGX-ST Approval: The LQN is conditional and subject to Quantum Healthcare’s compliance with all SGX-ST listing requirements and obtaining shareholders’ approval for the debt conversion and directors’ fees capitalisation.
• Tight Timeline: The placement shares must be placed out within 7 market days from the date of the LQN, indicating an imminent and rapid dilution event.
• Shareholder Approval Required: Issuance of shares for debt conversion and directors’ fees settlement will require explicit shareholder approval, adding an extra layer of governance.

Potential Price-Sensitive Issues

• Significant Dilution: The issuance of over 4.3 billion new shares (combined from placement, debt conversion, and directors’ fees capitalisation) will dramatically expand the company’s share base. Existing shareholders should prepare for substantial dilution of their ownership and voting power.
• Strategic Restructuring: The conversion of debt to equity and the payment of directors’ fees in shares suggest the company is actively managing its balance sheet—possibly in response to liquidity challenges or to strengthen its financial position for future growth.
• Not an Endorsement: The SGX-ST’s granting of the LQN should not be interpreted as an endorsement of the merits of the placement, conversion, or the company’s overall prospects.

Next Steps and Further Announcements

The company has stated it will make additional disclosures as further material developments occur regarding these proposals. Investors should closely monitor for updates, especially regarding the outcome of the required shareholder approvals and the actual placement results.

Conclusion: High-Impact Corporate Actions Ahead

This announcement represents a pivotal moment for Quantum Healthcare Limited. The massive new share issuance, debt conversion, and directors’ fees capitalisation are likely to have a material impact on both the company’s capital structure and its share price. Investors are strongly advised to assess the dilution implications and to stay alert for further updates from the company.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should perform their own due diligence and consult with professional advisors before making investment decisions. The Singapore Exchange Securities Trading Limited does not take responsibility for the content of this article.

View Quantum Health Historical chart here